Comparisons Between Dexmedetomidine and Magnesium Sulfate in Controlled Hypotension During Rhinoplasty Surgeries

Hypotension Clinical Trial

Official title:

Dexmedetomidine Versus Magnesium Sulfate in Controlled Hypotension During Rhinoplasty Surgeries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05880693
• Other study ID #: Sameh
• Status: Completed
• Phase: Phase 1
• Start date: January 1, 2022
• Est. completion date: May 1, 2023

Study information

• Verified date: May 2023
• Source: Azhar University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

General anesthesia organizes the best option for controlled blood pressure during rhinoplasty surgery. The primary agent applied in controlling hypotension should have particular unique characteristics. The dexmedetomidine central and peripheral sympatholytic performance is usually indicated by low blood pressure and low heart rate. magnesium sulfate is among the best agents used.

Description:

This is a prospective comparative randomized study. 56 patients got enrolled and then divided into two groups. Group 1 received dexmedetomidine (n=28), while the group 2 received magnesium sulfate (n=28). MAP, as well as heart rate, were recorded. Surgeon satisfaction was approximated for the surgical field quality. The amount of blood loss during the entire process was measured. The score of pain was evaluated using the NRS rating scale. Sedation score through Ramsey sedation score. The time required for the first requirement of analgesia was also recorded as well as intraoperative and postoperative problems.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: May 1, 2023
• Est. primary completion date: April 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. 18-60 years old

2. ASA (American Society of Anesthesiologists) grading I and II

3. patients undergo rhinoplasty surgery under general anesthesia

Exclusion Criteria:

1. The pregnant ladies

2. patients suffering from hypertension ischemic heart diseases renal insufficiency, neuromuscular diseases, hepatic impairment

3. cerebrovascular inadequacy and diabetic neuropathy, coagulopathies,

4. patients taking antiplatelets

5. Refused study,

6. patients of age < 18 or > 60 were unauthorized from the study.

Related Conditions & MeSH terms

• Hypotension

Intervention

Drug:
• Dexmedetomidine
Group 1 received dexmedetomidine
• Magnesium sulfate
the group 2 received magnesium sulfate

Locations

Country	Name	City	State
Egypt	Mohamed gawad Abdel aboelsuod	Cairo

Sponsors (2)

Lead Sponsor	Collaborator
mohamed	Azhar University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome was to determine the bleeding score	The primary outcome was to determine the bleeding score, the secondary outcomes included the mean arterial pressure as well as heart rate aiming to arrive at a surgical field free from the blood through controlled Hypotension, determination of surgeon satisfaction, and operation time, they also aided in anesthesia recovery through the use of the Aldrete score, Ramsey sedation score, and the first analgesia postoperative requirement.	24 hours postoperative period